Latest News and Press Releases

-- OLINVYK commercial supply on track and available in November Company funded through Q4 2022, including OLINVYK commercialization -- Company to host conference call at 8:30 a.m. ET on Monday,...

-- Posters highlight improvements in respiratory safety and gastrointestinal tolerability associated with OLINVYK (oliceridine) injection vs. IV morphine -- CHESTERBROOK, Pa., Oct. 05, 2020 ...

-- Live presentation highlighting TRV027 as a potential treatment for COVID-19 acute respiratory distress syndrome (ARDS) / abnormal clotting Posters on OLINVYK benefit-risk profile and TRV250 Phase...

- H.C. Wainwright: 22nd Annual Global Investment Conference -September 14th - Cantor Fitzgerald Virtual Global Healthcare Conference - September 17th -Oppenheimer Fall Healthcare Life Sciences...

-- Publication in Anesthesiology: Favorable benefit-risk profile for OLINVYK (oliceridine) injection as measured by clinical utility function analysis Publication in Clinical Drug Investigation:...

-- TRV027 is a novel AT1 receptor selective agonist with the potential to treat acute lung damage / abnormal blood clotting associated with COVID-19 The Company expects to report topline data in Q1...

-- $3 million milestone payment for U.S. approval of OLINVYK™ (oliceridine) injection Additional approval and commercialization milestone payments expected as well as 10% royalties on net sales in...

CHESTERBROOK, Pa., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central...

CHESTERBROOK, Pa., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) (“Trevena” or the “Company”), a biopharmaceutical company focused on the development and commercialization of novel...

CHESTERBROOK, Pa., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...